Taken together, these findings pinpoint a previously unidentified role of the GLP-1/GLP-1R axis in the pathogenesis of CAVD and indicate that liraglutide may serve as a potential therapeutic drug for preventing aortic valve calcification. The gene discussed is GLP1R; the disease is congenital bilateral aplasia of vas deferens from CFTR mutation.